


Amendments to the claims:

1. (Currently amended) A method for treating a subject with an allergic condition, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (I) below:



wherein:

$R^1$  is hydrogen, azido, halogen,  $C_{1-5}$  alkoxy, hydroxy,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, cyano, nitro,  $R^7R^8N$ ,  $C_{2-8}$  acyl,  $R^9OC=O$ ,  $R^{10}R^{11}NC=O$ , or  $R^{10}R^{11}NSO_2$ ; or  $R^1$  is taken together with W as described below;

$R^2$  is hydrogen, halogen,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl,  $C_{1-5}$  haloalkyl, cyano, or  $R^{48}R^{49}N$ ;

alternatively,  $R^1$  and  $R^2$  can be taken together to form an optionally substituted 5- to 7- membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic;

each of  $R^3$  and  $R^4$  is independently hydrogen or  $C_{1-5}$  alkyl;

each of  $R^5$  and  $R^6$  is independently hydrogen,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkylthio, halogen, or a 4-7 membered carbocyclyl or heterocyclyl;

$R^{40}$  is H,  $C_{+5}$  alkyl,  $C_{2-5}$  alkenyl, phenyl, benzyl, phenethyl,  $C_{+5}$  heterocyclyl, ( $C_{+5}$  heterocyclyl) $C_{+5}$  alkylene, amino, or mono- or di( $C_{+5}$  alkyl)amino, or  $R^{68}OR^{59}$ , wherein  $R^{58}$  is H,  $C_{+5}$  alkyl,  $C_{2-5}$  alkenyl, phenyl, benzyl, phenethyl,  $C_{+5}$  heterocyclyl, or ( $C_{+5}$  heterocyclyl) $C_{+5}$  alkylene and  $R^{69}$  is  $C_{+5}$  alkylene, phenylene, or divalent  $C_{+5}$  heterocyclyl; and

$R^{62}$  can be H in addition to the values for  $R^{40}$ ;

- $R^7$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, naphthyl,  $C_{1-5}$  heterocyclyl,  $C_{2-8}$  acyl, aroyl,  $R^{27}OC=O$ ,  $R^{28}R^{29}NC=O$ ,  $R^{27}SO$ ,  $R^{27}SO_2$ , or  $R^{28}R^{29}NSO_2$ ;
- $R^8$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, or  $C_{1-5}$  heterocyclyl;  
alternatively,  $R^7$  and  $R^8$  can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- $R^9$  is  $C_{1-5}$  alkyl, phenyl, naphthyl, or  $C_{1-5}$  heterocyclyl;
- $R^{21}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, naphthyl,  $C_{1-5}$  heterocyclyl,  $C_{2-8}$  acyl, aroyl,  $R^{30}OC=O$ ,  $R^{31}R^{32}NC=O$ ,  $R^{30}SO$ ,  $R^{30}SO_2$ , or  $R^{31}R^{32}NSO_2$ ;
- $R^{22}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, or  $C_{1-5}$  heterocyclyl;  
alternatively,  $R^{21}$  and  $R^{22}$  can be taken together to form an optionally substituted 4- to 7-membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- each of  $R^{23}$ ,  $R^{26}$ ,  $R^{27}$ ,  $R^{30}$ ,  $R^{33}$ ,  $R^{44}$ ,  $R^{45}$ , and  $R^{50}$  is  $C_{1-5}$  alkyl, phenyl, naphthyl, or  $C_{1-5}$  heterocyclyl;
- $R^{24}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, naphthyl,  $C_{1-5}$  heterocyclyl,  $C_{2-8}$  acyl, aroyl,  $R^{33}OC=O$ ,  $R^{34}R^{35}NC=O$ ,  $R^{33}SO$ ,  $R^{33}SO_2$ , or  $R^{34}R^{35}NSO_2$ ;
- $R^{25}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, or  $C_{1-5}$  heterocyclyl;  
alternatively,  $R^{24}$  and  $R^{25}$  can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- each of  $R^{10}$  and  $R^{11}$  is independently hydrogen,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, phenyl, or  $C_{1-5}$  heterocyclyl;  
alternatively,  $R^{10}$  and  $R^{11}$  or can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- each of  $R^{28}$ ,  $R^{29}$ ,  $R^{31}$ ,  $R^{32}$ ,  $R^{34}$ ,  $R^{35}$ ,  $R^{46}$ ,  $R^{47}$ ,  $R^{51}$  and  $R^{52}$  is independently hydrogen,  $C_{1-5}$  alkyl, phenyl, or  $C_{1-5}$  heterocyclyl;  
alternatively,  $R^{28}$  and  $R^{29}$ ,  $R^{31}$  and  $R^{32}$ ,  $R^{34}$  and  $R^{35}$ ,  $R^{46}$  and  $R^{47}$ , or  $R^{51}$  and  $R^{52}$ , independently, can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be

- saturated, unsaturated or aromatic;
- n is 1;
- G represents C<sub>3-6</sub> alkenediyl or C<sub>3-6</sub> alkanediyl, optionally substituted with hydroxy, halogen, C<sub>1-5</sub> alkyl, C<sub>1-5</sub> alkoxy, oxo, hydroximino, CO<sub>2</sub>R<sup>60</sup>, R<sup>60</sup>R<sup>61</sup>NCO<sub>2</sub>, (L)-C<sub>1-4</sub> alkylene-, (L)-C<sub>1-5</sub> alkoxy, N<sub>3</sub>, or [(L)-C<sub>1-5</sub> alkylene]amino;
- each of R<sup>60</sup> and R<sup>61</sup> is independently hydrogen, C<sub>1-5</sub> alkyl, C<sub>3-5</sub> alkenyl, phenyl, benzyl, phenethyl, or C<sub>1-5</sub> heterocyclyl; alternatively R<sup>60</sup> and R<sup>61</sup>, can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- L is amino, mono- or di-C<sub>1-5</sub> alkylamino, pyrrolidinyl, morpholinyl, piperidinyl, homopiperidinyl, or piperazinyl, where available ring nitrogens may be optionally substituted with C<sub>1-5</sub> alkyl, benzyl, C<sub>2-5</sub> acyl, C<sub>1-5</sub> alkylsulfonyl or C<sub>1-5</sub> alkyloxycarbonyl;
- X is nitrogen or R<sup>12</sup>C;
- Y is nitrogen or R<sup>13</sup>C;
- Z is nitrogen or R<sup>14</sup>C;
- R<sup>12</sup> is hydrogen, halogen, C<sub>1-5</sub> alkoxy, C<sub>1-5</sub> alkyl, C<sub>2-5</sub> alkenyl, cyano, nitro, R<sup>21</sup>R<sup>22</sup>N, C<sub>2-8</sub> acyl, C<sub>1-5</sub> haloalkyl, C<sub>1-5</sub> heterocyclyl, (C<sub>1-5</sub> heterocyclyl)C<sub>1-5</sub> alkylene, R<sup>23</sup>OC=O, R<sup>23</sup>O(C=O)NH-, R<sup>23</sup>SO, R<sup>22</sup>NHCO-, R<sup>22</sup>NH(C=O)NH-, R<sup>23</sup>(C<sub>1-4</sub> alkylene)NHCO-, R<sup>23</sup>SO<sub>2</sub>, or R<sup>23</sup>SO<sub>2</sub>NH-;
- R<sup>13</sup> is hydrogen, halogen, C<sub>1-5</sub> alkoxy, C<sub>1-5</sub> alkyl, C<sub>2-5</sub> alkenyl, cyano, nitro, R<sup>42</sup>R<sup>43</sup>N, C<sub>2-8</sub> acyl, C<sub>1-5</sub> haloalkyl, C<sub>1-5</sub> heterocyclyl, (C<sub>1-5</sub> heterocyclyl)C<sub>1-5</sub> alkylene, R<sup>44</sup>OC=O, R<sup>44</sup>O(C=O)NH-, R<sup>44</sup>SO, R<sup>43</sup>NHCO-, R<sup>43</sup>NH(C=O)NH-, R<sup>44</sup>(C<sub>1-4</sub> alkylene)NHCO-, R<sup>44</sup>SO<sub>2</sub>, or R<sup>44</sup>SO<sub>2</sub>NH-;
- R<sup>14</sup> is hydrogen, halogen, C<sub>1-5</sub> alkoxy, C<sub>1-5</sub> alkyl, C<sub>2-5</sub> alkenyl, cyano, nitro, R<sup>24</sup>R<sup>25</sup>N, C<sub>2-8</sub> acyl, C<sub>1-5</sub> haloalkyl, C<sub>1-5</sub> heterocyclyl, (C<sub>1-5</sub> heterocyclyl)C<sub>1-5</sub> alkylene, R<sup>26</sup>OC=O, R<sup>26</sup>O(C=O)NH-, R<sup>26</sup>SO, R<sup>25</sup>NHCO-, R<sup>25</sup>NH(C=O)NH-, R<sup>26</sup>(C<sub>1-4</sub> alkylene)NHCO-, R<sup>26</sup>SO<sub>2</sub>, or R<sup>26</sup>SO<sub>2</sub>NH-;
- alternatively, R<sup>12</sup> and R<sup>13</sup> or R<sup>12</sup> and R<sup>2</sup> or R<sup>13</sup> and R<sup>14</sup> can be taken together to form an optionally substituted 5- to 6- membered carbocyclic or

heterocyclic ring, which ring may be unsaturated or aromatic;

Ar represents a monocyclic or bicyclic aryl or heteroaryl ring, optionally substituted with between 1 and 3 substituents selected from halogen, C<sub>1-5</sub> alkoxy, C<sub>1-5</sub> alkyl, C<sub>2-5</sub> alkenyl, cyano, azido, nitro, R<sup>15</sup>R<sup>16</sup>N, R<sup>17</sup>SO<sub>2</sub>, R<sup>17</sup>S, R<sup>17</sup>SO, R<sup>17</sup>OC=O, R<sup>15</sup>R<sup>16</sup>NC=O, C<sub>1-5</sub> haloalkyl, C<sub>1-5</sub> haloalkoxy, C<sub>1-5</sub> haloalkylthio, and C<sub>1-5</sub> alkylthio;

R<sup>15</sup> is hydrogen, C<sub>1-5</sub> alkyl, C<sub>3-5</sub> alkenyl, phenyl, benzyl, C<sub>1-5</sub> heterocyclyl, C<sub>2-8</sub> acyl, aroyl, R<sup>53</sup>OC=O, R<sup>54</sup>R<sup>55</sup>NC=O, R<sup>53</sup>S, R<sup>53</sup>SO, R<sup>53</sup>SO<sub>2</sub>, or R<sup>54</sup>R<sup>55</sup>NSO<sub>2</sub>;


R<sup>16</sup> is hydrogen, C<sub>1-5</sub> alkyl, C<sub>3-5</sub> alkenyl, phenyl, benzyl, or C<sub>1-5</sub> heterocyclyl; alternatively, R<sup>15</sup> and R<sup>16</sup> can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

each of R<sup>17</sup> and R<sup>53</sup> is C<sub>1-5</sub> alkyl, phenyl, or C<sub>1-5</sub> heterocyclyl;


each of R<sup>54</sup> and R<sup>55</sup> is independently hydrogen, C<sub>1-5</sub> alkyl, C<sub>2-5</sub> alkenyl, phenyl, benzyl, or C<sub>1-5</sub> heterocyclyl;

alternatively, R<sup>54</sup> and R<sup>55</sup> can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

W represents SO<sub>2</sub>, C=O, CHR<sup>20</sup>, or a covalent bond; or W and R<sup>1</sup>, taken together with the 6-membered ring to which they are both attached, form one of the following two formulae:



(I)(a)



(I)(b)

wherein X<sub>a</sub> is O, S, or N; and X<sub>b</sub> is O, S or SO<sub>2</sub>;

R<sup>20</sup> is hydrogen, C<sub>1-5</sub> alkyl, phenyl, benzyl, naphthyl, or C<sub>1-5</sub> heterocyclyl;

- $R^{42}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, naphthyl,  $C_{1-5}$  heterocyclyl,  $C_{2-8}$  acyl, aroyl,  $R^{45}OC=O$ ,  $R^{46}R^{47}NC=O$ ,  $R^{45}SO$ ,  $R^{45}SO_2$ , or  $R^{46}R^{47}NSO_2$ ;
- $R^{43}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, or  $C_{1-5}$  heterocyclyl; alternatively,  $R^{42}$  and  $R^{43}$  can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- $R^{44}$  is  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, phenyl, naphthyl, or  $C_{1-5}$  heterocyclyl;
- $R^{48}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, naphthyl,  $C_{1-5}$  heterocyclyl,  $C_{2-8}$  acyl, aroyl,  $R^{50}OC=O$ ,  $R^{51}R^{52}NC=O$ ,  $R^{50}SO$ ,  $R^{50}SO_2$ , or  $R^{51}R^{52}NSO_2$ ;
- $R^{49}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, or  $C_{1-5}$  heterocyclyl; alternatively,  $R^{48}$  and  $R^{49}$  can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; and

wherein each of the above hydrocarbyl or heterocarbyl groups, unless otherwise indicated, and in addition to any specified substituents, is optionally and independently substituted with between 1 and 3 substituents selected from methyl, halomethyl, hydroxymethyl, halo, hydroxy, amino, nitro, cyano,  $C_{1-5}$  alkyl,  $C_{1-5}$  alkoxy,  $-COOH$ ,  $C_{2-6}$  acyl,  $[di(C_{1-4} \text{ alkyl})amino]C_{2-5}$  alkylene,  $[di(C_{1-4} \text{ alkyl})amino] C_{2-5}$  alkyl-NH-CO-, and  $C_{1-5}$  haloalkoxy;

or a pharmaceutically acceptable salt, ester, or amide thereof.

2. (Previously presented) A method of claim 1, wherein each of  $R^3$  and  $R^4$  is hydrogen; Ar represents a six membered ring, optionally substituted with between 1 and 2 substituents selected from halogen,  $C_{1-5}$  alkyl, cyano, nitro,  $R^{15}R^{16}N$ ,  $CF_3$  and  $OCF_3$ ;  $R^{12}$  is hydrogen,  $R^{23}SO$ , or  $R^{23}SO_2$ ;  $R^{13}$  is hydrogen,  $R^{44}SO$ , or  $R^{44}SO_2$ ;  $R^{14}$  is hydrogen, halogen,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkyl, cyano, nitro, or  $R^{24}R^{25}N$ ; and G is  $C_3$  alkanediyl, optionally substituted with hydroxy, (L)- $C_{1-5}$  alkyloxy-, or (L)- $C_{1-5}$  alkylamino.

3. (Previously presented) A method of claim 2, wherein Ar is phenyl.

4. (Canceled)

5. (Canceled)

6. (Previously presented) A method of claim 1, wherein said compound is:

1-[3-(3,4-Dichloro-phenyl)-pyrazol-1-yl]-3-(4-o-tolyl-piperazin-1-yl)-propan-2-ol.

7. (Canceled)

8. (Previously presented) A method of claim 1, wherein said pharmaceutical composition is formulated in a dosage amount appropriate for the treatment of an allergic condition.

9. (Previously presented) A method of claim 1, wherein said condition is asthma.

10. (Previously presented) A method of claim 2, wherein said condition is asthma.

11. (Previously presented) A method of claim 3, wherein said condition is asthma.

12. (Currently amended) A method of claim ~~[[7]]~~6, wherein said condition is asthma.